Verdinexor (ATG-527) is a unique Selective Inhibitor of Nuclear Export (SINE) compound currently under clinical evaluation as an anti-viral agent. Verdinexor has novel dual mechanism of action that it inhibits of replication of viruses that utilize Exportin 1 (XPO1/CRM1) machinery for some aspect of their life cycle, while contributing to symptom relief due to suppression of cytokine-mediated inflammatory responses. We are in partnership with Karyopharm Therapeutics for clinical development, manufacturing and commercialization of verdinexor in mainland China, Taiwan, Hong Kong, Macau, South Korea and ASEAN countries.
Pre-clinical studies have demonstrated verdinexor’s broad spectrum anti-viral activity including pandemic influenza strains and other viral classes, such as human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), hepatitis C virus (HCV), etc. Phase 1 first-in-human study of verdinexor in healthy volunteers has been completed. Verdinexor was found to be generally safe and well tolerated. Mild-to-moderate adverse events of similar number and grade as placebo were reported, but no serious or severe adverse events. We plan to initiate clinical studies of verdinexor as a treatment for influenza.